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GM1 gangliosidosis is an autosomal recessive lysosomal storage disorder caused by an 
enzyme deficiency of β-galactosidase (β-gal) leading to toxic accumulation of GM1 ganglioside 
in the central nervous system (CNS) and progressive neurodegeneration. Adeno-associated 
virus (AAV) mediated gene delivery of lysosomal enzymes to the CNS has shown great 
potential for the treatment of lysosomal storage diseases with neurological involvement. In this 
work we use MALDI mass spectrometry imaging (MSI) to assess the spatial distribution of 
gangliosides, ganglioside metabolites and related lipids in a GM1 gangliosidosis mouse brain 
model following adeno-associated virus (AAV) gene therapy. 
 
Deficiency of β-galactosidase enzyme in a β-gal-/- mouse brain showed an overall 8-fold 
increase in GM1 relative to the control by MSI analysis, with specific spatial localization based 
on its ceramide content. Bilateral thalamic injection of AAVrh10-gal in β-gal-/- mice significantly 
reduced GM1 levels relative to untreated β-gal-/- mice. The therapeutic efficacy of this approach 
is through distribution of functional enzyme via axonal transport through the extensive 
connectivity of the thalamus with most of the brain, with some exceptions such as the temporal 
cortex. Accordingly MSI showed AAV gene therapy reduced GM1 nearly to the control levels in 
all regions of the brain except in the temporal cerebral cortex. This correlated with low levels of 
gal in this brain region as assessed by histochemical staining of tissue sections. MSI also 
detected asialo-GM1 and other ganglioside metabolites elevated in untreated β-gal-/- mice, 
which were also reduced after AAV therapy. Interestingly sulfated galactocereberosides 
reduced in the myelin sheath in untreated β-gal-/- mice were restored to normal levels after AAV 
therapy. Overall, this study demonstrates that MALDI MSI can be used to map specific target 
analytes and their metabolites while also offering the ability to detect unanticipated effects 
caused by gene therapy. 
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